Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 15/15 micrograms/0.3 mL suspension for injection vial, Pfizer Australia Pty Ltd, CON-1078
Product name
COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 15/15 micrograms/0.3 mL suspension for injection vial
Sponsor name
Pfizer Australia Pty Ltd
Consent start
Consent no.
CON-1078
Standard
of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product will be supplied with International labels.
Conditions imposed
The product must be supplied with the labels that were considered and agreed to
as part of the evaluation under section 9D(3) of the Therapeutic Goods Act 1989,
being the 'International Labels' evaluated in submission.
Therapeutic product type
Prescription medicines